Bearing Point Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bearing Point Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3M	Buy	23,472 +2,120	+10%	+$265K	0.47%	63
2025 Q4	$2.6M	Buy	21,352 +4,831	+29%	+$554K	0.41%	67
2025 Q3	$1.66M	Buy	16,521 +640	+4%	+$57.6K	0.28%	74
2025 Q2	$1.32M	Sell	15,881 -43,274	-73%	-$3.45M	0.24%	77
2025 Q1	$4.8M	Buy	59,155 +1,131	+2%	+$101K	1.02%	38
2024 Q4	$5.23M	Buy	+58,024	New	+$5.62M	1.09%	34

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bearing Point Capital's XBI Position: Q1 2026 in Review

Bearing Point Capital increased its State Street SPDR S&P Biotech ETF (XBI) stake by 9.9% in Q1 2026, buying an estimated $265K and bringing the position to 23,472 shares worth $3M. The position accounts for 0.47% of the portfolio, ranked #63.

Bearing Point Capital first reported a position in XBI in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.23M in Q4 2024. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Bearing Point Capital held 23,472 shares of State Street SPDR S&P Biotech ETF worth $3M as of Q1 2026.
Bearing Point Capital bought 2,120 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $265K.
State Street SPDR S&P Biotech ETF made up 0.47% of Bearing Point Capital's portfolio in Q1 2026, its #63 holding.
Bearing Point Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 6 quarters since.
Bearing Point Capital's State Street SPDR S&P Biotech ETF position peaked at $5.23M in Q4 2024.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Bearing Point Capital's 13F filing for Q1 2026, filed 7 May 2026.